抗病毒药物阻断乙型肝炎母婴传播的研究进展

发布时间：2018-01-31 12:46

本文关键词： 肝炎乙型慢性疾病传播垂直抗病毒药拉米夫定母婴阻断替比夫定替诺福韦综述　出处：《天津医药》2016年03期 　论文类型：期刊论文

【摘要】：乙型肝炎病毒感染是一个世界性的公共卫生问题。在亚洲地区,母婴垂直传播是发生慢性感染的主要原因。对于体内高病毒载量的孕妇分娩的新生儿即使在产后进行适当的联合免疫接种,仍有10%~15%的母婴垂直传播率。因此,如何在孕期有效地阻断母婴垂直传播,以及应用抗病毒治疗的安全性问题是孕期管理乙型病毒性肝炎患者所面临的挑战。大量研究显示,体内高病毒载量的孕妇在孕晚期应用抗病毒药物(包括拉米夫定、替比夫定、替诺福韦)能够有效地降低母婴垂直传播率。本文就抗病毒药物阻断乙型肝炎母婴传播的相关研究进展进行综述。
[Abstract]:Hepatitis B virus infection is a worldwide public health problem. Vertical mother-to-child transmission is the main cause of chronic infection. For newborns born to pregnant women with high viral load, even after delivery, appropriate combined immunization is carried out. There are still 10 or 15% of vertical mother-to-child transmission. Therefore, how to effectively block mother-to-child vertical transmission during pregnancy. And the safety of antiviral therapy is a challenge to the management of hepatitis B patients during pregnancy. A large number of studies show that. Pregnant women with high viral loads were given antiviral drugs (including lamivudine and tibivudine) in late pregnancy. Tenofovir) can effectively reduce the rate of vertical mother-to-child transmission. This article reviews the progress of antiviral drugs in blocking mother-to-child transmission of hepatitis B.
【作者单位】：天津市第三中心医院妇产科;
【分类号】：R714.251
【正文快照】： 乙型肝炎病毒(HBV)感染是一个世界性的公共卫生问题。据世界卫生组织(WHO)统计,全球约有3.5~3.6亿HBV携带者,而中国是高发地区,HBV携带者多达1.2亿,其中约有30%~50%的HBV感染是通过母婴垂直传播所致[1]。因此,如何有效地阻断HBV母婴垂直传播已经成为全球关注的热点。目前,研究

【相似文献】